About DNAnexus
DNAnexus is a company based in Mountain View (United States) founded in 2009. DNAnexus has raised $472.55 million across 11 funding rounds from investors including Regeneron Pharmaceuticals, Blackstone and TPG. DNAnexus offers products and services including DNAnexus Platform, Bioinformatics Tools, and Collaboration Services. DNAnexus operates in a competitive market with competitors including Cytel, Genomics, Seven Bridges Genomics, Metagenomi and Ampersand, among others.
- Headquarter Mountain View, United States
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dnanexus, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$472.55 M (USD)
in 11 rounds
-
Latest Funding Round
$200 M (USD), Series H
Mar 08, 2022
-
Investors
Regeneron Pharmaceuticals
& 17 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DNAnexus
DNAnexus offers a comprehensive portfolio of products and services, including DNAnexus Platform, Bioinformatics Tools, and Collaboration Services.
Cloud-based tool for organizing and analyzing omics datasets securely.
Suite of apps for processing and visualizing genomic data efficiently.
Environment for team-based data sharing and compliance management.
People of DNAnexus
Unlock access to complete
Unlock access to complete
Software Development Team
53 people
Leadership Team
21 people
Senior Team
11 people
Principal Team
8 people
Product Management Team
7 people
Sales and Marketing
6 people
Human Resources and Administration
5 people
Finance and Accounting
4 people
Unlock access to complete
Funding Insights of DNAnexus
DNAnexus has successfully raised a total of $472.55M across 11 strategic funding rounds. The most recent funding activity was a Series H round of $200 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in DNAnexus
DNAnexus has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Regeneron Pharmaceuticals, Blackstone and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked |
Investor details for DNAnexus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DNAnexus
Investment portfolio details for DNAnexus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DNAnexus
Detailed financials for DNAnexus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dnanexus Comparisons
Peer comparison for DNAnexus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DNAnexus
DNAnexus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytel, Genomics, Seven Bridges Genomics, Metagenomi and Ampersand, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Data analysis and statistical solutions are provided for life sciences.
|
|
| Locked | Locked | Locked |
Genomic risk assessment and prevention platform is provided.
|
|
| Locked | Locked | Locked |
Cloud-based platform to analyze, store, and act on genomic data.
|
|
| Locked | Locked | Locked |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| Locked | Locked | Locked |
Programmable medicines are developed to target and treat multiple diseases.
|
Detailed competitors of DNAnexus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dnanexus
Complete news archive for DNAnexus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DNAnexus
DNAnexus was founded in 2009.
DNAnexus is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Richard Daly is the current CEO of DNAnexus.
DNAnexus is a funded company, having raised a total of $472.55M across 11 funding rounds to date.
DNAnexus was founded in 2009 and is headquartered in Mountain View, United States. Tools for cloud-based genome informatics and data management are offered to enterprises involved in genomic medicine. Raw sequencing data is analyzed through the platform, while genomic information is integrated with clinical and phenotypic data. Seamless collaboration among organizations is facilitated in this sector.
DNAnexus's top competitors include Cytel, Metagenomi and Ampersand.
DNAnexus offers DNAnexus Platform, Bioinformatics Tools, and Collaboration Services.
DNAnexus has 18 investors. Key investors include Regeneron Pharmaceuticals, Blackstone, TPG, HHS, and MidCap Financial.
The valuation of DNAnexus is $600M as of Mar 2022.